News

ivWatch Names Kathy Cox as Chief Financial Officer

ivWatch, LLC, inventor of the first and only continuous IV infiltration detection technology, appointments Kathy Cox to Chief Financial Officer. With over 23 years of experience, including 15 years in the medical device manufacturing and healthcare markets, Cox will strengthen the ivWatch leadership team and will provide expertise in driving business growth and operational efficiencies. She will lead the Accounting and Finance functions and report directly to President and Chief Executive Officer Gary Warren.

“Kathy is an exciting addition to our leadership team,” said Gary Warren, President and CEO, ivWatch. “Her strength as a leader at several medical device manufacturers and healthcare companies both privately owned and those held by global publicly-traded parent companies will be invaluable as we continue to grow our company, execute against our long-term strategies, and work to deliver breakthrough technologies to hospitals around the globe.”

“I am thrilled to join ivWatch and work alongside a team of inventors that will continue to improve patient safety and care through relentless innovation,” said Kathy Cox. “The company has a proven track record of putting people first to advance IV therapy and I am excited to bring my knowledge and experience throughout my career to help drive the trajectory of ivWatch and fulfill its mission.”

Prior to joining ivWatch, Cox held a series of executive positions for 12 years within Solesis, an operating division of Michelin and Fenner PLC, including Director/General Manager. She also held the role of Finance Director at Charter Medical and at Xeridiem Medical Devices. Over the course of her career, Cox has developed technical expertise in all aspects of corporate finance, financial planning, and accounting. Her Director/General Manager experience provides her with a strategic business view and commercial mindset that assists in communication of financial data across functional areas of a corporation. She specializes in leading transformative change in teams, processes, and systems to support revenue growth.

Cox, an active CPA since 2000, graduated from Florida State University in Tallahassee, Florida with a B.S. in Accounting.

Recent News

10/22/2026

Lilly breaks ground in Richmond to expand American manufacturing of next-generation cancer medicines, advancing its build-out of 10 new U.S. sites since 2020

Eli Lilly and Company (NYSE: LLY) broke ground today on a new $5 billion manufacturing facility just west of Richmond, Virginia, in Goochland County, one of 10 new U.S. manufacturing sites announced since 2020 and one of five among them that will produce active pharmaceutical ingredients (API). As part of the company’s more than $50 …

10/21/2026

United Therapeutics Expands Organ Manufacturing Capabilities with Opening of Third Designated Pathogen-Free Xenograft Production Facility

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the opening of its third Designated Pathogen-Free (DPF) facility, The Dr. Bartley P. Griffith and Dr. Robert A. Montgomery Xenograft Production Facility, in Houston, Texas. United Therapeutics opened its first DPF facility in Christiansburg, Va. in 2024 to produce xenografts for ongoing clinical trials. …

10/20/2026

Supernus Reaches Key Milestone Toward Proposed Merger with Indivior Following Shareholder Approval

Supernus Pharmaceuticals, Inc. welcomed the decisive backing of shareholders today, who formally voted to approve the pending all-stock merger of equals. This vote marks an important milestone toward completing the merger announced in August 2026, with closing anticipated on November 2, 2026, subject to customary closing conditions. Following closing, the combined organization will officially commence …